Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.40 |
| ▸ | METAP1 | P53582 | 2/20 | 0.39 |
| ▸ | METAP2 | P50579 | 1/20 | 0.39 |
| ▸ | CBFB | Q13951 | 1/20 | 0.39 |
| ▸ | AMY1A | P0DUB6 | 7/20 | 0.39 |
| ▸ | FABP6 | P51161 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | GUSB | P08236 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.37 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.36 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5067947 | 0.99 | ATM (0.39) | ATMNPC1RAB9AERAP1METAP1 | |
| Trifluoroacetic Acid SCHEMBL5067914 | 0.89 | HPSE (0.37) | ATMNPC1RAB9AERAP1METAP1 | |
| SCHEMBL3456828 | 0.81 | KDM4E (0.46) | NPC1RAB9AMETAP1METAP2MAPT | |
| Hydrochloric Acid SCHEMBL5067911 | 0.80 | KDM4E (0.45) | NPC1RAB9AMETAP1METAP2MAPT | |
| SCHEMBL3456715 | 0.78 | ATM (0.38) | ATMNPC1RAB9AERAP1METAP1 | |
| SCHEMBL3455100 | 0.75 | BRD4 (0.38) | ATMNPC1RAB9AERAP1METAP1 | |
| SCHEMBL5951979 | 0.74 | SOS1 (0.45) | METAP1METAP2CBFBAMY1AFABP6 | |
| SCHEMBL3462996 | 0.73 | ALDH1A1 (0.36) | ATMNPC1RAB9AERAP1METAP1 | |
| SCHEMBL3455109 | 0.73 | NPC1 (0.40) | ATMNPC1RAB9AERAP1METAP1 | |
| SCHEMBL14031952 | 0.73 | HPSE (0.41) | ATMNPC1RAB9AERAP1AMY1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2251340-A1 | Substituted tetrahydro-1h-pyrazolo[3,4-c] pyridines, compositions containing same and use thereof | Aventis Pharma S.A. (FR) | 2010-11-17 | — | — | EP | disclosed |
| EP-2251340-A1 | Substituted tetrahydro-1h-pyrazolo[3,4-c] pyridines, compositions containing same and use thereof | Aventis Pharma S.A. (FR) | 2010-11-17 | — | — | EP | disclosed |
| US-7435820-B2 | Substituted tetrahydro-1H-pyrazolo [3,4-c]pyridines compositions comprising them, and use | AVENTIS PHARMA S.A. (FR) | 2008-10-14 | — | — | US | disclosed |
| US-7435820-B2 | Substituted tetrahydro-1H-pyrazolo [3,4-c]pyridines compositions comprising them, and use | AVENTIS PHARMA S.A. (FR) | 2008-10-14 | — | — | US | disclosed |
| US-7435820-B2 | Substituted tetrahydro-1H-pyrazolo [3,4-c]pyridines compositions comprising them, and use | AVENTIS PHARMA S.A. (FR) | 2008-10-14 | — | — | US | disclosed |
| US-7109340-B2 | Substituted tetrahydro-1H-pyrazolo [3,4-c] pyridines, compositions comprising them, and use | AVENTIS PHARMA S.A. (FR) | 2006-09-19 | — | — | US | disclosed |
| US-20060199837-A1 | SUBSTITUTED TETRAHYDRO-1H-PYRAZOLO [3,4-C]PYRIDINES COMPOSITIONS COMPRISING THEM, AND USE | AVENTIS PHARMA S.A. (FR) | 2006-09-07 | — | — | US | disclosed |
| EP-1646632-A2 | SUBSTITUTED TETRAHYDRO-1 I H /I -PYRAZOLO 3,4-C|PYRIDINES, COMPOSITIONS CONTAINING SAME AND USE | Aventis Pharma S.A. (FR) | 2006-04-19 | — | — | EP | disclosed |
| US-20050096345-A1 | Substituted tetrahydro-1H-pyrazolo [3,4-c] pyridines, compositions comprising them, and use | AVENTIS PHARMA S.A. (FR) | 2005-05-05 | — | — | US | disclosed |
| WO-2005007653-A2 | SUBSTITUTED TETRAHYDRO-1H-PYRAZOLO[3,4-C]PYRIDINES, COMPOSITIONS CONTAINING SAME AND USE | AVENTIS PHARMA S.A. (FR) | 2005-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199837-A1 | SUBSTITUTED TETRAHYDRO-1H-PYRAZOLO [3,4-C]PYRIDINES COMPOSITIONS COMPRISING THEM, AND USE | BRD4, TP53, HCCS | ATM 1123/4885NPC1 4105/4885RAB9A 1322/4885 |
| US-20050096345-A1 | Substituted tetrahydro-1H-pyrazolo [3,4-c] pyridines, compositions comprising them, and use | BRD4, TP53, HCCS | ATM 995/4885NPC1 3940/4885RAB9A 1433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.